The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Definium Therapeutics Inc shares valued at $73,623 were sold by Karlin Daniel on Dec 26 ’25. At $13.15 per share, Karlin Daniel sold 5,600 shares. The insider’s holdings dropped to 425,025 shares worth approximately $6.54 million following the completion of this transaction.
Also, Barrow Robert sold 25,791 shares, netting a total of over 339,072 in proceeds. Following the sale of shares at $13.15 each, the insider now holds 778,477 shares.
Before that, Sullivan Mark had sold 11,276 shares from its account. In a trade valued at $148,244, the Chief Legal Officer traded Definium Therapeutics Inc shares for $13.15 each. Upon closing the transaction, the insider’s holdings decreased to 11,276 shares, worth approximately $4.35 million.
As published in their initiating research note from Needham on October 13, 2025, Definium Therapeutics Inc [DFTX] has been a Buy and the price target has been revised to $28. As of January 28, 2025, Evercore ISI has initiated its “an Outperform” rating for DFTX. Earlier on December 20, 2024, Chardan Capital Markets initiated its rating. Their recommendation was “a Buy” for DFTX stock.
Analyzing DFTX Stock Performance
On last trading session, Definium Therapeutics Inc [NASDAQ: DFTX] rose 2.40% to $15.38. The stock’s lowest price that day was $14.75, but it reached a high of $15.49 in the same session. During the last five days, there has been a surge of approximately 4.63%. Over the course of the year, Definium Therapeutics Inc shares have jumped approximately 140.50%.
Support And Resistance Levels for Definium Therapeutics Inc (DFTX)
RSI (Relative Strength Index) is 67.48 on the 14-day chart, showing neutral technical sentiment.
